Обзор материалов конференции экспертов в области терапии рака почки


Волкова М.И.

В обзоре представлены материалы конференции экспертов в области лечения рака почки (Стамбул, Турция, 12–13 марта 2010 г.), отражающие современные стандарты лекарственной терапии распространенного рака почки. В первой линии лечения светлоклеточного рака групп хорошего и промежуточного прогноза MSKCC рекомендовано назначение сунитиниба или комбинации бевацизумаба с интерфероном ?, или пазопаниба. В группе плохого прогноза MSKCC стандартом первой линии терапии является темсиролимус. При цитокинрефрактерном раке почки показано назначение сорафениба. Единственным препаратом, продемонстрировавшим эффективность при опухолях, рефрактерных к ингибиторам тирозинкиназ в III фазе исследований, является эверолимус.

Литература


1. de Reijke TM, Bellmunt J, van Poppel H et al. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 2009;45:765–73.


2. Ljungberg B, Nigel C. Cowan, Damian C. Hanbury, et al. EAU Guidelines on Renal Cell Carcinoma: The 2010 Update. Eur Urol 2010;58:398–406.


3. Escudier B, Kataja V. Renal cell carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(S4):iv81–iv82.


4. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer 2010;2.


5. Motzer Robert J, Hutson Thomas E, Pharm D, et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. N Engl J Med 2007;356:115–24.


6. Rini Brian I, Halabi S, Rosenberg JE, et al. Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206. JCO 2008;26:5422–28.


7. Rini BI, Halabi S, Rosenberg J, et al. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. J Clin Oncol 2009;27:abLBA5019.


8. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet2007;370:2103–11.


9. Escudier BJ, Bellmunt J, Negrier S, et al. Final results of the phase III, randomized, doubleblind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). JCO 2009;27(15S Suppl.):5020.


10. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. J Clin Oncol 2010;28:1061–68.


11. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. N Engl J Med 2007;356:2271–81.


12. Motzer Robert J, Hutson Thomas E, Pharm D, et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2007;356:124–134.


13. Escudier Bernard, Szczylik Cezary, Hutson Thomas E. Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol 2010;27:1280–89.


14. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma. Final Results and Analysis of Prognostic Factors. Cancer Month 2010 [in press].


15. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma. J ClinOncol 2004;22:454–63.


16. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–72.


17. Korhonen P, Haas T, Zuber E, et al. Overall survival among metastatic renal cell carcinoma (MRCC) patients corrected for crossover using a rank preserving structural failure time (RPSFT) model: analyses from the everolimus phase III trial (abstract P-7155 and poster #7155) Eur J Cancer 2009;7(2 Suppl.):440.


18. Wiederkehr D, Howe CJ, Casciano R, et al. Overall survival among metastatic renal cell carcinoma patients corrected for crossover using inverse probability of censoring weights: analysis from the RECORD-1 phase 3 trial. Eur J Cancer2009;7S2:abstr. 7131.


19. Sablin MP, Negrier S, Ravaud A, et al. Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma. J Urol 2009;182:29–34.


20. Dudek AZ, Zolnierek J, Dham A, et al. Sequential Therapy With Sorafenib and Sunitinib in Renal Cell Carcinoma. Cancer 2009;115:61–73.


21. Sablin MP, Negrierb S, Ravaudc A, et al. Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma. J Urol 2009;182(1):29–34.


22. Richter S, Pfister D, Thüer D, et al. Second-line target therapy of advanced renal cell carcinoma with sunitinib or sorafenib. Onkologie2008;31(Suppl. 4):684.


23. Di Lorenzo G, Cartenü G, Autorino R, et al. Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer. J ClinOncol 2009;27:4469–74.


24. Shepard DR, Rini BI, Garcia JA, et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 2008;26:ab5123.


25. Jac J, Amato RJ, Giessinger S, et al. A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy. JClin Oncol 2008;26:ab5113.


26. Merchan JR, Pitot HC, Qin R, et al. Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): Safety and activity in RTKI refractory RCC patients. J Clin Oncol2009;27ab5039.


27. Gruenwald V, Seidel C, Fenner M, et al. Antitumor activity of tyrosine kinase inhibitors (TKI) after failure of RAD001 in metastatic renal cell carcinoma (mRCC). ASCO 2010 Genitourinary Cancers Symposium. General Poster Session E: Testis, Bladder, Renal and Other GU Neoplasms Abstract No: 414.


28. Ravaud A, Digue L, Trufflandier N, et al. VEGFR TKI ‘resistance’ or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma. Ann Oncol 2010;21:431–32.


29. Bellmunt J, Szczylik C, Feingold J, et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. AnnOncol 2008;19:1387–92.


30. Torisel [package insert]. Philadelphia, PA; Wyeth Pharmaceuticals Inc., 2008.


31. Инструкция по применению препарата Афинитор (ЛСР-002260/10–18.03.10)


32. Duran I, Siu LL, Oza AM, et al Characterization of the lung toxicity of the cell cycle inhibitor temisirolimus. Eur J Cancer 2006;42,1875–80.


Похожие статьи


Бионика Медиа